Rodabe Bhatt

Rodabe Bhatt specializes in the treatment of advanced stage IV melanoma with a focus on overcoming resistance to checkpoint immunotherapy and targeted BRAF/MEK inhibitor therapy. Her research investigates mechanisms of immune exclusion and T cell dysfunction in melanoma that underlie primary and acquired resistance to anti-PD-1 therapy, seeking actionable targets for combination approaches. She has conducted clinical investigations of novel therapies in patients with checkpoint inhibitor-refractory advanced melanoma including LAG-3 inhibitors and adoptive T cell therapy strategies. Her translational work connects tumor microenvironment immune profiling with clinical outcomes to identify biomarkers guiding treatment selection in advanced melanoma.